Pfizer Inc (PFE) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite.

Total Cash From Operating Activities Chart for Pfizer Inc

Pfizer Inc (PFE) operating cash flow for FY2025 was USD 11.7B, a -8.2% change from FY2024. Pfizer Inc's operating cash flow grew from USD 655.8M in 1989 to USD 11.7B in 2025 (1684.8% over 36 years). Operating cash flow compound annual growth rate: 5-year CAGR of -4.1%, 10-year CAGR of -2.1%, 20-year CAGR of -1.1%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$149.33B
Implied Share Price
$26.20
Enterprise Value
$196.32B
Revenue (TTM)
$63.70B
EBITDA
$25.38B
Profit Margin
6.80%
Trailing P/E
34.03
Forward P/E
8.67
Price/Book (MRQ)
1.70
Price/Sales (TTM)
2.34
EV/EBITDA
14.55
EV/Revenue
3.08
Dividend Yield
6.66%
Book Value
$14.95
Free Cash Flow (FY2025)
$9.08B
Free Cash Flow Yield
6.08%

Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.